ACURX PHARMACEUTICALS LLC (NASDAQ: ACXP)

ACURX PHARMACEUTICALS LLC

NASDAQ: ACXP (Acurx Pharmaceuticals, Inc.)

Last update: 23 hours ago

4.62

-0.15 (-3.14%)

Add to watchlist

Previous Close	4.77
Open	4.99
Volume	89,876
Avg. Volume (3M)	339,587
Market Cap	7,321,683

Price / Book

2.05

52 Weeks Range	3.80 (-17%) — 44.90 (871%)
Earnings Date	13 Nov 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Mixed	Bearish
	Biotechnology (Global)	Mixed	Bearish
Stock	Acurx Pharmaceuticals, Inc.	Bullish	Bullish

AIStockmoo Score

1.6

Analyst Consensus	3.5
Insider Activity	NA
Price Volatility	0.5
Technical Moving Averages	5.0
Technical Oscillators	-2.5
Average	1.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
ACXP	7 M	-	-	2.05
MRNA	9 B	-	-	1.05
HRMY	2 B	-	11.90	2.83
MESO	2 B	-	-	4.47
ABCL	1 B	-	-	1.24
CVAC	1 B	-	5.37	1.78

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Sector	Healthcare
Industry	Biotechnology
Investment Style	Small Value
% Held by Insiders	10.95%
% Held by Institutions	18.21%

Ownership

Name	Date	Shares Held
Prospect Financial Services Llc	30 Jun 2025	14,839
Sabby Management, Llc	30 Jun 2025	4,095
O'brien Greene & Co. Inc	30 Jun 2025	3,000
Vanguard Capital Wealth Advisors	30 Jun 2025	2,300
Act Advisors, Llc.	30 Jun 2025	2,298

52 Weeks Range	3.80 (-17%) — 44.90 (871%)
Median	31.00 (571.00%)
Total	1 Buy

Firm	Date	Target Price	Call	Price @ Call
HC Wainwright & Co.	12 Aug 2025	31.00 (571.00%)	Buy	4.44

Date	Type	Details
29 Aug 2025	Announcement	New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Frank Aquila, and Mercurity Fintech (NASDAQ: MFH)
12 Aug 2025	Announcement	Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
03 Aug 2025	Announcement	New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion Rate
31 Jul 2025	Announcement	Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
24 Jul 2025	Announcement	Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
17 Jun 2025	Announcement	Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
17 Jun 2025	Announcement	/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
09 Jun 2025	Announcement	New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
09 Jun 2025	Announcement	Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Current Ratio (MRQ)	1.93
Operating Cash Flow (TTM)	-9.37 M
Levered Free Cash Flow (TTM)	-4.87 M

Return on Assets (TTM)	-106.68%
Return on Equity (TTM)	-285.79%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)